Spatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumors and breast cancer
Single-cell RNA-seq · human · 50 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart. Read from the summary: GEO's own type field only says 'expression profiling by sequencing', so confirm it in the paper.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 50 samples: 11 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE299631_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1275757 and SRA study SRP592141. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 28 samples.
How we read this: 11 replicated groups read from 50 sample titles; they account for 28 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9042305 Mouse, Visium ST, Primary tumor, #1 Mouse, Visium ST, Prima…
- GSM9042306 Mouse, Visium ST, Primary tumor, #2 Mouse, Visium ST, Prima…
- GSM9042307 Mouse, Visium ST, TAC 12dpt, #3a
- GSM9042308 Mouse, Visium ST, Mammary gland, #4 Mouse, Visium ST, Mamma…
- GSM9042309 Mouse, Visium ST, Mammary gland, #5 Mouse, Visium ST, Mamma…
- GSM9042310 Mouse, Visium ST, Primary tumor, #6 Mouse, Visium ST, Prima…
- GSM9042311 Mouse, Visium ST, Primary tumor, #7 Mouse, Visium ST, Prima…
- GSM9042312 Mouse, Visium ST, TAC 12dpt, #8a
- GSM9042313 Mouse, Visium ST, Primary tumor, #9a
- GSM9042314 Mouse, Visium ST, Cisplatin 7dpt, #10 Mouse, Visium ST, Cispl…
- GSM9042315 Mouse, Visium ST, Cisplatin 12dpt, #11 Mouse, Visium ST, Cispl…
- GSM9042316 Mouse, Visium ST, Cisplatin Recurrent, #12 Mouse, Visium ST, Cispl…
- GSM9042317 Mouse, Visium ST, Primary tumor, #9b
- GSM9042318 Mouse, Visium ST, TAC 7dpt, #13 Mouse, Visium ST, TAC 7…
- GSM9042319 Mouse, Visium ST, TAC 12dpt, #8b
- GSM9042320 Mouse, Visium ST, TAC Recurrent, #14 Mouse, Visium ST, TAC R…
- GSM9042321 Mouse, Visium ST, TAC 7dpt, #15 Mouse, Visium ST, TAC 7…
- GSM9042322 Mouse, Visium ST, TAC 12dpt, #3b
- GSM9042323 Mouse, Visium ST, TAC Recurrent, #16 Mouse, Visium ST, TAC R…
- GSM9042324 Mouse, Visium ST, Primary tumor, #17a
- GSM9042325 Mouse, Visium ST, Primary tumor, #17b
- GSM9042326 Mouse, Visium ST, Cisplatin 7dpt, #18 Mouse, Visium ST, Cispl…
- GSM9042327 Mouse, Visium ST, Cisplatin 12dpt, #19 Mouse, Visium ST, Cispl…
- GSM9042328 Mouse, Visium ST, Cisplatin Recurrent, #20 Mouse, Visium ST, Cispl…
- GSM9042329 Mouse, Visium ST, Primary tumor, #21 Mouse, Visium ST, Prima…
- GSM9042330 Mouse, Visium ST, Cisplatin 4hpt, #22 Mouse, Visium ST, Cispl…
- GSM9042331 Mouse, Visium ST, Cisplatin 24hpt, #23 Mouse, Visium ST, Cispl…
- GSM9042332 Mouse, Visium ST, Cisplatin 24hpt 12mg/kg, #24
- GSM9042333 Mouse, Visium ST, Primary tumor, #25 Mouse, Visium ST, Prima…
- GSM9042334 Mouse, Visium ST, Cisplatin 4hpt, #26 Mouse, Visium ST, Cispl…
- GSM9042335 Mouse, Visium ST, Cisplatin 24hpt, #27 Mouse, Visium ST, Cispl…
- GSM9042336 Mouse, Visium ST, Cisplatin 12dpt, #28 Mouse, Visium ST, Cispl…
- GSM9042337 Human, Visium ST, Residual tumor, #1 Human, Visium ST, Resid…
- GSM9042338 Human, Visium ST, Residual tumor, #2 Human, Visium ST, Resid…
- GSM9042339 Human, Visium ST, Primary tumor, #3 Human, Visium ST, Prima…
- GSM9042340 Human, Visium ST, Primary tumor, #4 Human, Visium ST, Prima…
- GSM9042341 Human, Visium ST, Residual tumor, #5 Human, Visium ST, Resid…
- GSM9042342 Mouse, scRNA-seq, Residual tumor, TAC, GFP+, #1a
- GSM9042343 Mouse, scRNA-seq, Residual tumor, TAC, GFP-, #1a
- GSM9042344 Mouse, scRNA-seq, Primary tumor, TAC, GFP+, #2a
+ 10 more — browse all 50 samples with per-sample file links →
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing · shares breast
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares breast
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing · shares breast
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares breast
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE270779 MYC couples SWI/SNF and metabolic reprogramming to sustain minimal residual disease in mTORC1-activated cancer cells 64 samples shares residual
- GSE270774 MYC couples SWI/SNF and metabolic reprogramming to sustain minimal residual disease in mTORC1-activated cancer cells [CUT&RUN, ATAC-seq] 32 samples shares residual
- GSE270777 MYC couples SWI/SNF and metabolic reprogramming to sustain minimal residual disease in mTORC1-activated cancer cells [RNA-seq] 18 samples shares residual
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.